Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Soundtrack at present: Iggy Pop, The Idiot.

Moderna CEO Stéphane Bancel is looking well beyond melanoma after the company’s personalized cancer vaccine, intismeran, succeeded in a pivotal Phase 3 trial. In an interview with STAT at the ESMO meeting in Madrid, Bancel said Moderna and partner Merck are racing to submit the vaccine for FDA approval, which he expects in 2027. The companies, he said, are also preparing to test it aggressively in other cancers.